In a non-blind randomized comparison of sotalol hydrochloride and methyldopa in essential hypertension, the two drugs were equivocal in effect in reaching a preset hypotensive aim, in the maximum decreases from the baseline and in the mean reductions per week from the baseline. Milligram for milligram, sotalol was about twice as potent as methyldopa. No volunteered side-effects were noted for methyldopa; 3/19 for sotalol.
Get full access to this article
View all access options for this article.
References
1.
KashemsantUReedCS (1974) Advances in Beta-adrenergic Blocking Therapy—Sotalol. Edited by AlanG Snart-IV-85 Excerpta Medica ICS 341, Amsterdam
2.
PrichardBNCBoakesAJ (1974) Advances in Beta-adrenergic Blocking Therapy—Sotalol. Edited by AlanG Snart-IV-7 Excerpta Medica ICS 341, Amsterdam
3.
SundquistHArstilaM (1974) Advances in Beta-adrenergic Blocking Therapy—Sotalol. Edited by AlanG Snart-IV-59 Excerpta Medica ICS 341, Amsterdam
4.
SundquistHAnttilaMArstilaM (1974) Antihypertensive effects of practolol and sotalol. Clinical Pharmacology and Therapeutics, 16, (3) Part I: 465
5.
VernioryAStaroukineMDelwicheFATelermanM (1976) Effect of sotalol on haemodynamics and renin-angiotensin-aldosterone system in hypertensive patients. Clinical Science and Molecular Medicine, 51, 9
6.
WardEE (1974) Advances in Beta-adrenergic Blocking Therapy—Sotalol. Edited by AlanG Snart-IV-46 Excerpta Medica ICS 341, Amsterdam
7.
YanV (1974) Advances in Beta-adrenergic Blocking Therapy—Sotalol. Edited by AlanG Snart-IV-86 Excerpta Medica ICS 341, Amsterdam
